

Metabolic Consequences of Hyperhomocysteinemia

Angela M Devlin, PhD

Child & Family Research Institute
Division of Endocrinology, Department of Pediatrics
University of British Columbia
Vancouver, Canada




Metabolic Consequences of HHcy

- Endothelial dysfunction (impaired vasodilatation) is a common feature of hyperhomocysteinemia
- What are the mechanisms?
- Homocysteine is metabolically linked to:
 - DNA methylation
 - Lipid metabolism


Where to start...

- DNA methylation (CpG methylation) regulates gene expression
- Allele-silencing of genomically imprinted genes
 - *H19/Igf2*
- Silencing of gene expression
 - *Fads2* (lipid metabolism)
 - *Nr3c1*

Homocysteine & DNA Methylation




Homocysteine & DNA Methylation



ADOMET = S-adenosylmethionine
ADOHCY = S-adenosylhomocysteine


Genomically Imprinted *H19/Igf2*

- *H19/Igf2* are well characterized reciprocally imprinted genes
- Biallelic expression of *H19* has been reported in human subjects with renal disease and HHcy
- Reversed by folate supplementation
(Ingrosso et al *Lancet* 2003; 361:1693-1699)
- *H19* is a good 'proof-of-concept' target to investigate the relevance of changes in AdoMet and AdoHcy to changes in DNA methylation and tissue-specific differences



- *H19* is expressed from the maternal allele, *Igf2* expressed from the paternal allele
- Expression is regulated by the methylation status of a differentially methylated domain (DMD)

(reviewed by Ideraabdullah & Bartolomei *Mut Res*, 2008, 647:77-85)



F1 Hybrid Offspring


B6 [Cbs +/+] x Cast
Control Diet

B6 [Cbs +/+] x Cast
HH Diet


B6 [Cbs +/-] x Cast
HH Diet

HH Diet = low folate, high methionine, sulfathiazole

Plasma Total Homocysteine




Liver AdoMet/AdoHcy



* $P < 0.01$, ** $P < 0.05$

Reduced liver methylation capacity with HHcy.




-4455 gactcccaa tcaacaag^Gt ¹ cggcttactc tctgcaaaga
 -4415 atcctttgtg tgtaaagacc agggttg²ccg ³ ⁴ cacggcggca
 -4375 gtgaagtctc ⁵ gtacat ⁶ cgca gtcctaaaa

G (C57BL/6J) allele → A (Cast allele) at nucleotide -4437

Identified a strain-specific variant that was used for allele-specific methylation.


Methylation Assay Reliability




100/0 75/25 50/50 25/75 0/100

% Maternal Allele / % Paternal Allele

Liver Maternal Allele




Decreased methylation of the maternal *H19* allele in liver from mice with HHcy.



No effect of HHcy on paternal *H19* allele methylation in liver.


Liver *H19* mRNA



monoallelic expression

* ** $P < 0.05$


Liver *Igf2* mRNA



monoallelic expression


Decreased levels of *Igf2* mRNA with decreased *H19* maternal allele methylation in liver from mice with HHcy.

Plasma Total Homocysteine




* ** $P < 0.05$

Brain AdoMet/AdoHcy




No effect of HHcy on brain methylation capacity.




*** $P < 0.05$

Increased methylation of the maternal *H19* allele in brain from mice with HHcy (despite no change in methylation capacity).




No effect of HHcy on paternal *H19* allele methylation in brain.

Brain *H19* mRNA



monoallelic expression

Brain *Igf2* mRNA




biallelic expression

Decreased levels of *H19* mRNA with increased methylation of the *H19* maternal allele in brain from mice with HHcy.

Summary: *H19/Igf2* & HHcy


- HHcy is associated with gene-specific changes in DNA methylation
- Changes in methylation are tissue specific
- Changes in DNA methylation can occur in tissues despite no changes in methylation capacity (AdoMet/AdoHcy)

Homocysteine & DNA Methylation




Plasma Homocysteine

$P < 0.001$




Liver AdoMet/AdoHcy

$P < 0.01$




Reduced liver methylation capacity with HHcy.


Intersection of Lipids & Methyl Metabolism



Phosphatidylethanolamine




Phosphatidylcholine



* $P < 0.01$

Increased liver phosphatidylethanolamine in HHcy.

Intersection of Lipids & Methyl Metabolism



n-6

linoleic acid (18:2)



γ -linolenic acid (18:3)



20:3



arachidonic acid (20:4)

n-3

α -linolenic acid (18:3)



18:4



20:4



EPA (20:5)



DHA (22:6)

n-6

linoleic acid (18:2)



γ-linolenic acid (18:3)



20:3



arachidonic acid (20:4)

delta-6 desaturase

+/-HH mice with HHcy



delta-6 desaturase

n-3

α-linolenic acid (18:3)



18:4



20:4



EPA (20:5)




DHA (22:6)




Mice with HHcy have lower levels of 20:4 n-6 and 22:6 n-3 in liver.


Fads2 mRNA



Delta-6 Desaturase Activity



Reduced expression of liver *Fads2* with HHcy.




Increased methylation of the *Fads2* promoter in liver.


HHcy & DNA Methylation

- Mice with HHcy have methylation silencing of *Fads2* expression and changes in long chain fatty acid composition in liver
- Vascular tissue?
- Targeted *Nr3c1* (encodes GR)
- Expression regulated by methylation (hippocampus)
- Glucocorticoids may have cardioprotective effects


Aorta *Nr3c1* mRNA




$P < 0.05$




Aorta GR protein




Reduced expression of aorta *Nr3c1* with HHcy







Sp1 binding to *Nr3c1*




Increased methylation of Sp1 binding sites but no change in Sp1 binding to *Nr3c1* in aorta.




$P < 0.05$

Increased methylation of the Nrf1 binding site in *Nr3c1* in aorta.




$P < 0.05$

Increased methylation of the Nrf1 binding site associated with decreased binding of Nrf1 to *Nr3c1* in aorta.



Aorta Nrf1 protein



Overall Summary & Conclusions

- Regulation of gene expression by DNA methylation may play a role in the pathology of HHcy
- Effect of HHcy on DNA methylation is tissue-specific and gene-specific
- AdoMet/AdoHcy is not always a good biomarker of changes in DNA methylation
- Alterations in liver fatty acid metabolism observed in mice with HHcy may be involved in the pathology of HHcy

Acknowledgements

Devlin Lab

Dian Sulistyoningrum
Eugene Wang
Melissa Glier
Mihai Cirstea
Kathy Ho
Julia Wei
Rachel Wade

Collaborators

Dr. Sheila M. Innis
University of British Columbia

Dr. Terry Bottiglieri
Baylor Institute of Metabolic
Disease

Dr. Steve Lentz
University of Iowa



Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology (CSATVB)
Société canadienne d'athérosclérose, de thrombose et de biologie vasculaire (SCATBV)